Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Rang in aandelen #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Aandeelprijs
$0.0001
Laatst gesynchroniseerd: 2026-07-02
Marktkapitalisatie
$2.20K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
CA
Handel Cotinga Pharmaceuticals Inc. (COTQF)

Categorie

Dividendrendementgeschiedenis voor Cotinga Pharmaceuticals Inc. (COTQF)
Het dividendrendement (TTM) van Cotinga Pharmaceuticals Inc. (aandelsymbool: COTQF) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Cotinga Pharmaceuticals Inc. (COTQF) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten